Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with BALVERSA® (erdafitinib) Versus Chemotherapy

Data from Cohort 1 of the Phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical standard-of-care chemotherapy MADRID, Oct. 21, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 2 randomized, open-label THOR-2 study evaluating BALVERSA® versus investigator […]

Related Keywords

Madrid ,Spain ,United Kingdom ,Clin Urol ,Obrian Kenney ,Indianj Urol ,Kiran Patel ,James Wf Catto ,Janssen Research Development ,Janssen Biotech Inc ,University Of Sheffield ,European Society For Medical Oncology Congress ,None Of Janssen Research Development ,European Society For Medical Oncology ,Astex Pharmaceuticals ,Clinical Development ,Companies Of Johnson ,Exchange Commission ,Drug Administration ,Janssen Pharmaceutical Companies Of Johnson ,Johnson ,Department Of Oncology ,Us Food Drug Administration ,Janssen Pharmaceutical Companies ,Bacillus Calmette Gu ,Proffered Paper Late Breaking Session ,European Society ,Medical Oncology ,Hazard Ratio ,Confidence Interval ,Vice President ,Solid Tumors ,Janssen Research ,Supplemental New Drug Application ,European Medicines Agency ,Janssen Pharmaceutica ,Soft Tissue Mineralization ,Fetal Toxicity ,Prescribing Information ,Pharmaceutical Companies ,Pulmonary Hypertension ,Janssen Biotech ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,With High Risk Non ,Muscle Invasive Bladder Cancer ,Who Received Prior Bacillus Calmette Gu ,Accessed September ,Participants With Advanced Solid Tumors ,Fibroblast Growth Factor Receptor ,Accessed May ,Unresponsive Non Muscle Invasive Bladder Cancer ,Current Treatment Landscape ,Novel Emerging Molecular ,Intj Mol ,